Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Recruiting · Phase 2 · NCT05890352
Conditions: Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
At a glance
- Research payments reported, 2025
- $4,265
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 227
About the trial
- Sponsor
- SWOG Cancer Research Network (with National Cancer Institute (NCI), BeiGene, Ipsen, Incyte Corporation)
- Tested
- Biospecimen Collection (procedure), Computed Tomography (procedure), Lenalidomide (drug), Magnetic Resonance Imaging (procedure), Positron Emission Tomography (procedure), Quality-of-Life Assessment (other), Questionnaire Administration (other), Tafasitamab (biological), Tazemetostat (drug), Zanubrutinib (drug)
- Dates
- Started 2023-09-26; completion 2029-12
- Results posted
- Not yet
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to…
From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $4,265 in research payments for this study in 2025 (2 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Hope Foundation $4,265
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.